# Johnson & Johnson Revenue

NYSE: JNJ · Reporting currency: USD

[Interactive page](https://beanvest.com/stock/jnj/revenue) · [JSON with these options](https://beanvest.com/stock/jnj/revenue.json?range=5Y&deductSbc=false&limit=200&offset=0&frequency=quarterly&wacc=7.9) · [Raw filing inputs](https://beanvest.com/api/v2/financials/jnj)

Frequency: quarterly. Newest first. Retrieved: 2026-10-23T15:28:34.599Z.
Coverage: 2009-06-28 to 2026-09-27. Rows 1–70 of 70.
Snapshot checked: 2026-10-19T21:59:30.430Z. Last validated: 2026-11-06T22:00:21.819Z.

## Definitions

- **Total revenue** (`total_revenue`, USD_millions): Reported consolidated revenue as tagged in the SEC filing, including all company businesses.

## Values

| Period | End date | Total revenue (USD_millions) |
| --- | --- | --- |
| 2026-Q3 | 2026-09-27 | 25399 |
| 2026-Q2 | 2026-06-28 | 25310 |
| 2026-Q1 | 2026-03-29 | 24062 |
| 2025-Q4 | 2025-12-28 | 24564 |
| 2025-Q3 | 2025-09-28 | 23993 |
| 2025-Q2 | 2025-06-29 | 23743 |
| 2025-Q1 | 2025-03-30 | 21893 |
| 2024-Q4 | 2024-12-29 | 22520 |
| 2024-Q3 | 2024-09-29 | 22471 |
| 2024-Q2 | 2024-06-30 | 22447 |
| 2024-Q1 | 2024-03-31 | 21383 |
| 2023-Q4 | 2023-12-31 | 21395 |
| 2023-Q3 | 2023-10-01 | 21351 |
| 2023-Q2 | 2023-07-02 | 25530 |
| 2023-Q1 | 2023-04-02 | 24746 |
| 2022-Q4 | 2023-01-01 | 19939 |
| 2022-Q3 | 2022-10-02 | 23791 |
| 2022-Q2 | 2022-07-03 | 24020 |
| 2022-Q1 | 2022-04-03 | 23426 |
| 2021-Q4 | 2022-01-02 | 24804 |
| 2021-Q3 | 2021-10-03 | 23338 |
| 2021-Q2 | 2021-07-04 | 23312 |
| 2021-Q1 | 2021-04-04 | 22321 |
| 2020-Q4 | 2021-01-03 | 22475 |
| 2020-Q3 | 2020-09-27 | 21082 |
| 2020-Q2 | 2020-06-28 | 18336 |
| 2020-Q1 | 2020-03-29 | 20691 |
| 2019-Q4 | 2019-12-29 | 20747 |
| 2019-Q3 | 2019-09-29 | 20729 |
| 2019-Q2 | 2019-06-30 | 20562 |
| 2019-Q1 | 2019-03-31 | 20021 |
| 2018-Q4 | 2018-12-30 | 20394 |
| 2018-Q3 | 2018-09-30 | 20348 |
| 2018-Q2 | 2018-07-01 | 20830 |
| 2018-Q1 | 2018-04-01 | 20009 |
| 2017-Q4 | 2017-12-31 | 20195 |
| 2017-Q3 | 2017-10-01 | 19650 |
| 2017-Q2 | 2017-07-02 | 18839 |
| 2017-Q1 | 2017-04-02 | 17766 |
| 2016-Q4 | 2017-01-01 | 18106 |
| 2016-Q3 | 2016-10-02 | 17820 |
| 2016-Q2 | 2016-07-03 | 18482 |
| 2016-Q1 | 2016-04-03 | 17482 |
| 2015-Q4 | 2016-01-03 | 17811 |
| 2015-Q3 | 2015-09-27 | 17102 |
| 2015-Q2 | 2015-06-28 | 17787 |
| 2015-Q1 | 2015-03-29 | 17374 |
| 2014-Q4 | 2014-12-28 | 18254 |
| 2014-Q3 | 2014-09-28 | 18467 |
| 2014-Q2 | 2014-06-29 | 19495 |
| 2014-Q1 | 2014-03-30 | 18115 |
| 2013-Q4 | 2013-12-29 | 18355 |
| 2013-Q3 | 2013-09-29 | 17575 |
| 2013-Q2 | 2013-06-30 | 17877 |
| 2013-Q1 | 2013-03-31 | 17505 |
| 2012-Q4 | 2012-12-30 | 17558 |
| 2012-Q3 | 2012-09-30 | 17052 |
| 2012-Q2 | 2012-07-01 | 16475 |
| 2012-Q1 | 2012-04-01 | 16139 |
| 2011-Q4 | 2012-01-01 | 16255 |
| 2011-Q3 | 2011-10-02 | 16005 |
| 2011-Q2 | 2011-07-03 | 16597 |
| 2011-Q1 | 2011-04-03 | 16173 |
| 2010-Q4 | 2011-01-02 | 15644 |
| 2010-Q3 | 2010-10-03 | 14982 |
| 2010-Q2 | 2010-07-04 | 15330 |
| 2010-Q1 | 2010-04-04 | 15631 |
| 2009-Q4 | 2010-01-03 | 16551 |
| 2009-Q3 | 2009-09-27 | 15081 |
| 2009-Q2 | 2009-06-28 | 15239 |

## Business drivers

Reviewed 2026-10-23T16:00:32.939Z. Independent reported series; these are not assumed to form an additive breakdown.

### Med Tech revenue

Reported quarterly Med Tech revenue. Unit: iso4217:USD. Cadence: quarterly.

| From | Through | Reported value | Source |
| --- | --- | --- | --- |
| 2025-03-31 | 2025-06-29 | 8541000000 | [Report filed 2026-07-23](https://www.sec.gov/Archives/edgar/data/200406/000020040626000153/jnj-20260628.htm) |
| 2025-06-30 | 2025-09-28 | 8430000000 | [Report filed 2026-10-21](https://www.sec.gov/Archives/edgar/data/200406/000020040626000197/jnj-20260927.htm) |
| 2026-03-30 | 2026-06-28 | 8926000000 | [Report filed 2026-07-23](https://www.sec.gov/Archives/edgar/data/200406/000020040626000153/jnj-20260628.htm) |
| 2026-06-29 | 2026-09-27 | 8642000000 | [Report filed 2026-10-21](https://www.sec.gov/Archives/edgar/data/200406/000020040626000197/jnj-20260927.htm) |

### Innovative Medicine revenue

Reported quarterly Innovative Medicine revenue. Unit: iso4217:USD. Cadence: quarterly.

| From | Through | Reported value | Source |
| --- | --- | --- | --- |
| 2025-03-31 | 2025-06-29 | 15202000000 | [Report filed 2026-07-23](https://www.sec.gov/Archives/edgar/data/200406/000020040626000153/jnj-20260628.htm) |
| 2025-06-30 | 2025-09-28 | 15563000000 | [Report filed 2026-10-21](https://www.sec.gov/Archives/edgar/data/200406/000020040626000197/jnj-20260927.htm) |
| 2026-03-30 | 2026-06-28 | 16384000000 | [Report filed 2026-07-23](https://www.sec.gov/Archives/edgar/data/200406/000020040626000153/jnj-20260628.htm) |
| 2026-06-29 | 2026-09-27 | 16757000000 | [Report filed 2026-10-21](https://www.sec.gov/Archives/edgar/data/200406/000020040626000197/jnj-20260927.htm) |

## Business disclosures

Reviewed 2026-10-23T16:00:45.643Z. Original dated quotations; initiatives and plans do not establish delivered results.

### Firelink™ DAC platform

Disclosure type: initiative.

> The Firelink™ DAC platform is designed to deliver highly selective protein degraders directly to cancer cells, enabling targeted activity while preserving healthy tissue—a key limitation of many current treatment approaches.

[Original disclosure 2026-07-29](https://www.sec.gov/Archives/edgar/data/200406/000020040626000163/exhibit991firefly.htm)

### Sail's in vivo CAR-T platform

Disclosure type: initiative.

> Johnson & Johnson will collaborate with Sail to advance its lead immune-mediated disease program and broader platform technology, with incentives to expand the application of Sail's in vivo CAR-T platform across additional therapeutic targets over time.

[Original disclosure 2026-07-29](https://www.sec.gov/Archives/edgar/data/200406/000020040626000163/exhibit992sail.htm)

## Sources

- [sec-0000200406-9ce98e50414e](https://data.sec.gov/api/xbrl/companyfacts/CIK0000200406.json) · Retrieved 2026-10-22T16:29:10.469Z · SHA-256 9ce98e50414e9a6704eaf485e1868c2298c6ae36acc85a82c0a3737485303be7
- [inline-0000200406-1c32a922ad6c](https://www.sec.gov/Archives/edgar/data/200406/000020040626000197/jnj-20260927.htm) · Retrieved 2026-10-22T16:29:10.469Z · SHA-256 1c32a922ad6c6c25ba706b8deb5c8b0e03f1d7312acaa0a50e7105ac2c7d72e8

## Data conventions

- Null means an unavailable input or undefined calculation, never zero. Values are unrounded; money and shares are in millions unless a column states otherwise.
- Fiscal periods use actual reporting start/end dates. Annual reported values are not constructed by adding quarterly EPS or weighted share counts. Partial years are labelled.
- FCF uses operating cash flow minus reported cash capital investment, preferring PPE purchases. The productive-assets fallback can also include software and intangibles. Acquisitions and noncash leases are excluded. Deduct SBC is an optional economic-cost scenario; missing SBC remains unavailable.
- SBC / FCF and SBC / OCF compare amounts from the same fiscal period. SBC / FCF always uses FCF before SBC deduction; nonpositive denominators are undefined and values above 100% remain valid.
- Capital allocation percentages describe available tracked cash uses, not all company spending or a fraction of OCF. Missing categories remain null, negative payments are excluded and SBC is noncash. Annual shares use reported annual amounts.
- Valuation uses completed, split-adjusted closes without dividend adjustment and a complete trailing year. Financial bases become eligible after publication; selected facts can contain later restatements. This is not a vintage-filings backtest.
- Mean and median use all valid observations in the selected date range before pagination. Historical pricing labels compare the latest positive value with its own median and do not estimate intrinsic fair value.
- Reporting currencies are retained without conversion. USD market capitalization, where available, is a separate dated Nasdaq snapshot.
- WACC is an editable US industry scenario across history, not a historical company cost of capital. Industry exclusions, missing inputs and pending filings remain explicit.
